DANIEL R. PASSERI - 25 Mar 2022 Form 4 Insider Report for Cue Biopharma, Inc. (CUE)

Role
CHIEF EXECUTIVE OFFICER, Director
Signature
/s/ Daniel Passeri by Colin Sandercock, attorney-in-fact
Issuer symbol
CUE
Transactions as of
25 Mar 2022
Net transactions value
$0
Form type
4
Filing time
29 Mar 2022, 16:08:19 UTC
Previous filing
08 Oct 2021
Next filing
04 Apr 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CUE Stock Option (right to buy) Award $0 +100,000 $0.000000 100,000 25 Mar 2022 Common Stock 100,000 $5.01 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1. This stock option grant becomes exercisable in eight equal semi-annual installments beginning September 25, 2022.